Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3604609 | 0.95 | TRPV1 (0.51) | TRPV1CA9DRD2DRD4SMN1; SMN2 | |
| SCHEMBL3602000 | 0.90 | DRD2 (0.43) | TRPV1DRD2DRD4SMN1; SMN2GAA | |
| SCHEMBL3597005 | 0.88 | CA9 (0.45) | TRPV1CA9DRD2DRD4SMN1; SMN2 | |
| SCHEMBL2062933 | 0.87 | CA9 (0.47) | TRPV1CA9GAAMAPTCRBN | |
| SCHEMBL3600796 | 0.86 | TSHR (0.46) | TRPV1CA9DRD2DRD4SMN1; SMN2 | |
| SCHEMBL3602346 | 0.85 | CA9 (0.43) | TRPV1CA9DRD2DRD4SMN1; SMN2 | |
| SCHEMBL3588944 | 0.85 | DRD2 (0.44) | TRPV1CA9DRD2DRD4GAA | |
| SCHEMBL3602310 | 0.85 | CA9 (0.47) | TRPV1CA9DRD2DRD4GAA | |
| SCHEMBL3588009 | 0.84 | CA9 (0.42) | TRPV1CA9DRD2DRD4SMN1; SMN2 | |
| SCHEMBL3584531 | 0.84 | TRPV1 (0.48) | TRPV1DRD2DRD4SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103635458-B | Trpv1 antagonists | 艾伯维公司 | 2016-10-19 | — | — | CN | disclosed |
| US-8969325-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8802711-B2 | TRPV1 antagonists | ABBVIE INC. (US) | 2014-08-12 | — | — | US | disclosed |
| CN-103635458-A | Trpv1 antagonists | ABBVIE INC | 2014-03-12 | — | — | CN | disclosed |
| EP-2688866-A1 | TRPV1 ANTAGONISTS | AbbVie Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013096226-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2012134943-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2012-10-04 | — | — | WO | disclosed |
| US-20120245163-A1 | TRPV1 Antagonists | ABBOTT LABORATORIES (US) | 2012-09-27 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
| CN-101589038-A | Heterocyclidene-N-(aryl)acetamide derivative | MOCHIDA PHARM CO LTD (JP) | 2009-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | TRPV1 2518/4885CA9 1531/4885DRD2 530/4885 |
| US-20130172334-A1 | TRPV1 ANTAGONISTS | TRPV1, MRGPRX1, MRGPRX4 | TRPV1 1/4885CA9 1695/4885DRD2 714/4885 |
| US-20120245163-A1 | TRPV1 Antagonists | TRPV1, TRPV3, TRPV6 | TRPV1 1/4885CA9 2015/4885DRD2 457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.